07:58 AM EDT, 07/16/2024 (MT Newswires) -- Philip Morris International's ( PM ) IQOS products continue to face opposition in the US, with six health and anti-tobacco groups recently campaigning against the US Food and Drug Administration's approval of the company's latest applications.

The campaign group, including American Lung Association, American Heart Association, and American Cancer Society Cancer Action Network, wrote to the FDA last month, urging the regulator to consider "various developments" before approving Philip Morris' ( PM ) application for the renewal of its exposure modification order for the IQOS 3 device and premarket authorization of ILUMA, the next-generation IQOS product.

The group said recent independent studies of IQOS in other countries failed to demonstrate the product's population-wide public health benefit, and Philip Morris ( PM ) has issued "misleading and deceptive statements" implying that the FDA determined that IQOS reduces the risk of disease.

The group also said the FDA's support for banning menthol cigarettes contradicts its approval of menthol-flavored IQOS products.

Philip Morris International ( PM ) did not immediately respond to MT Newswires' request for comment.

Price: 105.06, Change: -0.01, Percent Change: -0.01